Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the safety of lecanemab-irmb in people with Alzheimers Disease in real-world clinical settings. The study focuses on monitoring specific adverse events related to amyloid-related imaging abnormalities such as edema and hemosiderin deposits, as well as other serious events like seizures, anaphylaxis, ischemic events in the central nervous system, and intracerebral hemorrhage. It also compares safety outcomes among participants with different baseline features and prior treatments. Participants prescribed lecanemab-irmb by their physicians as part of routine care will be observed through the ALZ-NET registry, which collects data from about 20,000 patients, including around 6,700 treated with lecanemab-irmb. This is a non-interventional study, meaning participants receive standard care without additional treatments assigned by the study. The safety of lecanemab-irmb will be assessed over up to 10 years using registry data. During the study, researchers will review reports of adverse events and exposures to lecanemab-irmb, focusing on imaging abnormalities and other serious health events. They will analyze risks related to genetic factors, prior Alzheimers treatments, and antithrombotic use. Data collection occurs continuously within the registry, allowing long-term monitoring of participants safety outcomes. The study runs from May 2025 through January 2035.
Actively Recruiting
Researchers are evaluating the safety of LEQEMBI in patients with Alzheimers disease in a real-world clinical setting. The study focuses on tracking specific events related to amyloid-related imaging abnormalities ARIA, including ARIA-edema ARIA-E, ARIA-hemosiderin deposition ARIA-H, symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage larger than 1 centimeter. The aim is to gather safety data over a long period while patients receive LEQEMBI treatment. This is an observational, non-interventional study where patients with Alzheimers disease are treated with LEQEMBI according to the approved prescribing information by their physician during routine clinical practice. Data will be collected from the South Korean JOY-ALZ registry, which tracks patients receiving this treatment. There is no placebo or comparator group, and treatment decisions are made prior to enrollment. Participants will be followed for up to 6 years, during which researchers will monitor and record the incidence and rates of adverse events of special interest, including ARIA-related events and other adverse drug reactions. They will also observe serious adverse events and reactions. The study collects real-world data to better understand the safety profile of LEQEMBI over time in the South Korean population with Alzheimers disease.
Actively Recruiting
This research aims to evaluate whether using an intervention website called Mosaic can improve patient-reported outcomes in adults with blood cancers who are undergoing allogeneic or autologous stem cell transplant. The study compares the intervention website to an educational control website, focusing on psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life. It also explores if improvements relate to patients preparedness, coping skills, stress levels, and personal factors like language, sex, race, ethnicity, and transplant type. Participants are randomly assigned to use either the intervention website, which offers experiential transplant information, coping and stress management training, and educational resources in English or Spanish, or the control website that provides similar coping and education materials without the experiential content. They use their assigned website throughout the study period. Participants complete five assessments one before the transplant and four follow-ups at 2, 4, 6, and 8 months post-transplant. Researchers monitor improvements in psychological distress, cancer-related distress, symptoms, and quality of life over time. The study includes safety checks and measures adherence to website use, with total participation lasting about eight months after transplant.